Pulmonary Vascular Disease: Pulmonary Vascular Disease: VTE |

Single Drug Approach With Edoxaban Is Effective and Safe for the Patients With Venous Thromboembolism FREE TO VIEW

Yusuke Hattori; Akihiro Tsuji; Jin Ueda; Shigefumi Fukui; Takeshi Ogo, MD; Norifumi Nakanishi
Author and Funding Information

National Cerebral and Cardiovascular Center, Suitashi, Japan

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;149(4_S):A526. doi:10.1016/j.chest.2016.02.548
Text Size: A A A
Published online

SESSION TITLE: Pulmonary Vascular Disease: VTE

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: Edoxaban is a direct inhibitor of activated factor X with a rapid onset of action. It is orally administered once daily, and has proven antithrombotic effect. In Hokusai-VTE Study, edoxaban, which was administered once daily after initial treatment with heparin (for at least 5 days) was noninferior to standard therapy and caused significantly less bleeding in patients with venous thromboembolism (VTE). However, it is uncertain whether single drug approach with edoxaban is effective and safe for acute VTE patients. The aim of this study is to establish the efficacy and safety of single drug approach with edoxaban

METHODS: All data were retrospectively collected from medical records. We collected the data of acute VTE patients, who was treated with edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60kg). The cases, whose initial treatment duration were over 48 hours, were excluded. We evaluated the efficacy and safety of single drug approach with edoxaban for acute VTE patients.

RESULTS: September 2014 and July 2015, 50 patients (62 ± 15 years old, 32 females) who were diagnosed with acute VTE, had edoxaban therapy in our center. 10 patients were excluded because of initial treatment duration > 48 hours. 40 patients (pulmonary embolism: 25 patients, deep vein thrombosis: 15 patients) were enrolled in this study. Mean follow up period was 6.0 ± 2.4 months. 39 patients of 40 had no reccurence until follow - up period. Moreover, no one had also a major bleeding until follow - up period.

CONCLUSIONS: Single drug approach with edoxaban is effective and safety for acute VTE patients.

CLINICAL IMPLICATIONS: In the future, edoxaban may also be used as single drug approach in the real world.

DISCLOSURE: The following authors have nothing to disclose: Yusuke Hattori, Akihiro Tsuji, Jin Ueda, Shigefumi Fukui, Takeshi Ogo, Norifumi Nakanishi

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543